Bowel Cleansing Clinical Trial
Official title:
A Post-marketing Drug Intensive Monitoring Study of Compound Sodium Picosulfate Granules for Bowel Preparation in Chinese Population
NCT number | NCT04852120 |
Other study ID # | 000373 |
Secondary ID | |
Status | Completed |
Phase | |
First received | |
Last updated | |
Start date | April 1, 2021 |
Est. completion date | December 31, 2022 |
Verified date | July 2023 |
Source | Ferring Pharmaceuticals |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
High-quality bowel preparation plays an important role in ensuring a safe and successful X-ray examination, endoscopy or some kinds of bowel surgeries. Inadequate bowel preparation may lead to incomplete examination of the colonic mucosa, may require increased operation time and difficulty, and incur the costs for rescheduling or performing other examinations. Early attention to the influencing factors of bowel cleansing effect and taking positive measures can effectively improve the success rate and diagnosis rate of endoscopic and radiological examinations, and reduce the possibility of postoperative complications and local infections. In 2019, China released the latest "Guidelines for Bowel Preparation Related to Digestive Endoscopy", emphasizing the importance of dietary restrictions and patient notification and education. The "Guideline" also recommends that sodium picosulfate, magnesium oxide, and anhydrous citric acid can be used for bowel preparation before endoscopy and is well tolerated (recommended strength: weak; evidence quality: moderate). The other used colonic cleansing agents also include polyethylene glycol (PEG) electrolyte powder, magnesium salt, sodium phosphate, mannitol and Chinese herbal medicine. Each carries its own properties, indications and safety profiles. Compound Sodium Picosulfate Granules is a compounded preparation consisting of sodium picosulfate and magnesium citrate. Each sachet contains 10 mg of sodium picosulfate, 3.5 g of magnesium oxide and 12.0 g of citric acid. It is white to slightly yellow crystalline powder, with a slight orange flavour. Sodium picosulfate is transformed by colonic bacteria to form an active metabolite: bis-(p-hydroxyphenyl)-pyridyl-2-methane, Bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM), which acts directly on the colonic mucosa to stimulate colonic peristalsis. Magnesium oxide and citric acid react to create magnesium citrate (when dispersed in a solution), which is an osmotic agent that causes water to be retained within the gastrointestinal tract. The stimulant laxative activity of sodium picosulfate together with the osmotic laxative activity of magnesium citrate produces a purgative effect, which can be used to clean the bowel prior to X-ray examination, endoscopy or bowel surgery. Since its first marketing in the United Kingdom (UK) in December 1980, Compound Sodium Picosulfate Granules has been approved in more than 80 countries and regions, including Germany (2010), France (2010), Spain (2011), Italy (2011), United States (2012) and Japan (2016), under the tradename PICOLAX, PICOPREP or PREPOPIK. In 2018, Compound Sodium Picosulfate Granules was officially approved in China with the indication: for preparation of bowel cleansing prior to X-ray examination, endoscopy or surgery when judged clinically necessary.
Status | Completed |
Enrollment | 3000 |
Est. completion date | December 31, 2022 |
Est. primary completion date | December 31, 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | N/A and older |
Eligibility | Inclusion Criteria: - Patients who have been prescribed Ferring Compound Sodium Picosulfate Granules - Agree to participate in this study and sign the informed consent form (ICF). Exclusion Criteria: - Patients who are enrolled in other on-going studies, which prohibit any participation in this non-interventional study. |
Country | Name | City | State |
---|---|---|---|
China | Ferring Investigational Site | Beijing | |
China | Ferring Investigational Site | Dalian | |
China | Ferring Investigational Site | Fuzhou | |
China | Ferring Investigational Site | Jingdezhen | |
China | Ferring Investigational Site | Nanjing | |
China | Ferring Investigational Site | Ningbo | |
China | Ferring Investigational Site | Qiqihar | |
China | Ferring Investigational Site | Xian |
Lead Sponsor | Collaborator |
---|---|
Ferring Pharmaceuticals | DeltaMed |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Incidence of Known Adverse Drug Reactions (ADRs) | An adverse drug reaction (ADR) is characterized by the suspicion of a causal relationship between the medicine and the occurrence, i.e. judged as being at least possibly related to treatment by the reporter or a reviewing health professional.
An ADR is a response to a medicinal product which is noxious and unintended. This includes adverse reactions which arise from: The use of a medical product within the terms of the marketing authorization; The use outside the terms of the marketing authorization, including overdose, off-label use, misuse, abuse and medication errors; Occupational exposure. |
Up to 37(+2) hours after drug administration | |
Primary | Occurrence of Unexpected Adverse Events (AEs)/ADRs | Adverse event (AE) is any untoward medical condition or the deterioration of a pre-existing medical condition in a patient or clinical investigation participant administered a pharmaceutical product and which does not necessarily have a causal relationship with the treatment. An AE can therefore be any unfavourable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not related to the medicinal product.
Unexpected adverse reaction refers to a drug reaction whose nature, severity, specificity, or outcome is not consistent with the term or description listed in the current local/regional label. This includes events that may be symptomatically and pathophysiological related to an event listed in the labelling but differ from the event because of greater severity or specificity. |
Up to 37(+2) hours after drug administration | |
Primary | Incidence and Risk Factors of Serious Adverse Events (SAEs)/Serious Adverse Drug Reactions (SADRs) | The incidence below is Syncope.
A serious adverse event (SAE) is defined as any untoward medical occurrence that at any dose that: Results in death Is life-threatening Is a congenital anomaly/birth defect Results in persistent or significant disability/incapacity Results in unplanned inpatient hospitalisation or prolongation of existing hospitalisation Is an important medical event that may jeopardise the participant or may require intervention to prevent one of the outcomes listed above |
Up to 37(+2) hours after drug administration |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02630680 -
Eziclen Drug Utilisation in Real Life Setting
|
||
Completed |
NCT05032794 -
Unrestricted Diet for Screening Colonoscopy
|
N/A | |
Completed |
NCT02239692 -
A Trial Comparing the PICOPREP Tailored Dosing Schedule to the PICOPREP Day-before Dosing Schedule for Colon Cleansing in Preparation for Colonoscopy
|
Phase 3 | |
Unknown status |
NCT01481714 -
Efficacy and Safety of Split-dose Citrafleet Administered From 2 to 6 Hours Before Morning Colonoscopies
|
Phase 4 | |
Completed |
NCT02321462 -
Efficacy, Safety and Tolerability of Eziclen in Adult Subjects Undergoing Colonoscopy
|
Phase 3 | |
Recruiting |
NCT04054388 -
LINE Re-education Before Colonoscopy to Confirm Optimal Bowel Cleansing
|
N/A | |
Completed |
NCT01864915 -
Prucalopride + Prucalopride Booster vs. Prucalopride + Picosalax Booster for the Colon Capsule
|
Phase 3 | |
Completed |
NCT03631446 -
Drug Use-Results Survey on Picoprep® Combination Powder
|
||
Recruiting |
NCT05354609 -
DWI MR-enterography Without or With Bowel Cleansing to Assess Intestinal Inflammatory Activity in the Follow-up of Crohn's Disease
|
N/A |